[ad_1]
PHOTO: Pixabay
Several studies have shown that the antiparasitic agent ivermectin is effective in the prevention and treatment of COVID-19. This is stated in a Frontline COVID-19 Critical Care Alliance summary, cited by the American medical portal “Healio”.
Paul Marrick, founder of the alliance and professor of pulmonology and critical care at a medical school in eastern Virginia, said that “Invermectin is a safe drug that is extremely cheap and affordable,” writes Dariknews.
The expert described the drug as a “gift to us, for its high activity against COVID-19.”
The researchers note that the drug is an antiparasitic drug that has been on the market for almost 40 years, and for this reason its discoverers won the Nobel Prize.
The alliance in question uses the drug in question in the early treatment of patients infected with the infection. In the protocol, people with the highest risk and vulnerability take the drug for the first and third days, and others for four weeks. Those who have been in contact with the virus receive the same dose on the first and third day. All groups also received a daily dose of vitamin D3, vitamin C, the antioxidants quercetin, zinc, and melatonin.
The results of studies based on this protocol demonstrate the efficacy in preventing infections after a person has been in contact with COVID-19. Marik also points out that, in addition to prevention, it demonstrates effective treatment of infection at the first symptoms, as well as even in hospitalized patients.
A summary of the existing scientific literature on the treatment of coronavirus with Invermectin indicates that the drug has a dual effect: not only in treatment but also in preventing infection.
The alliance notes that in a randomized clinical trial in Egypt of medical workers who have regular contact with people infected and sick with COVID-19, only 2% of those who received Invermectin (they also wear personal protective equipment: masks, helmets, goggles etc. have tested positive.In comparison, 10% of medical contact workers equipped with personal protective equipment were infected.
Another large study was conducted with a total of 400 patients, divided into four groups, two of them with patients with mild to moderate form and two more with severe disease.
People with mild to moderate form received one dose per day of Invermectin, and the other group of mild and moderate cases – the antimalarial drug “hydroxychloroquine” twice a day. The percentages are impressive: 1% of mild to moderate patients who took Invermectin developed a more severe form. For comparison, 22% of the other group had complications.
For the most seriously ill, 4% of the antiparasitic group had complications, while with the antimalarial agent the efficacy was much lower: 30% of this group had deteriorated. The parameters are similar with mortality: 2% of people in the Invermectin group die after complications from coronavirus infection, while in patients treated with hydroxychloroquine, these rates rise to 20%, the researchers said.
[ad_2]
